ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

HIO Healthcare Inv

14.75
0.00 (0.00%)
Last Updated: 00:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Healthcare Inv LSE:HIO London Ordinary Share GB00B94T6Y14 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 14.75 0.00 00:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Collagen Solutions PLC Collagen Solutions Supply Agreement with BBI

07/12/2015 7:00am

RNS Non-Regulatory


TIDMCOS

Collagen Solutions PLC

07 December 2015

Collagen Solutions Plc

(the "Company" or the "Group")

Supply agreement with BBI Solutions

Collagen Solutions plc (AIM: COS), the developer and manufacturer of medical grade collagen components for use in regenerative medicine, medical devices and in-vitro diagnostics, announces the execution of a supply agreement between Collagen Solutions (UK) Ltd and BBI Solutions OEM Limited ("BBI").

The supply agreement which will be for an initial three year period and on a rolling annual basis thereafter, will encompass the supply of Collagen Solutions' medical grade materials to support the research, pre-clinical and clinical development programmes of BBI's broad customer base.

Commenting on the agreement, Dr Stewart White, CEO of Collagen Solutions, said: "BBI has a renowned reputation for their knowledge in the reagent supply, diagnostics and development space and are therefore an excellent partner to enable collagen users to access our high quality medical grade GMP approved materials. We are very pleased to be working with Lyn and the team in Cardiff."

Lyn Rees, CEO of BBI Solutions added: "Our mission is to deliver exceptional products and technologies through innovation, partnership, effective delivery and collaboration. By working alongside the team at Collagen Solutions we can build on our expertise and reputation for supplying critical biological products into regulated markets. Our developing customer base in the advanced cellular and regenerative medicine markets are increasingly looking for collagen compounds. As a result, it was important for us to find a partner who can supply the high grade collagen they require consistently. Through this relationship with Collagen Solutions, we can continue to build our brand, improve the quality of people's lives and further our goals for the future in this transformational area of healthcare."

Enquiries:

 
 Collagen Solutions Plc 
 David Evans, Chairman                  Tel: 07740 084 452 
 Stewart White, CEO                     Tel: 0141 648 9100 
 
 Panmure Gordon & Co (Nominated         Tel: 0207 8862 714 
  Advisor and Broker)                   Tel: 0207 886 2905 
  Robert Naylor (Corporate 
  Finance) 
  Maisie Atkinson (Corporate 
  Broking) 
 
 Walbrook PR Ltd                     Tel: 020 7933 8780 or 
                                   collagen@walbrookpr.com 
 Anna Dunphy                            Mob: 07876 741 001 
 Mike Wort                              Mob: 07900 608 002 
 
 BBI Solutions 
 Lyn Rees, CEO                          Tel: 029 207 47232 
 

About BBI Solutions OEM Limited.

BBI Solutions is a leading supplier of biological raw materials and finished test platforms to the in-vitro diagnostic market. With over 50 years' experience, we have grown from a small specialist company to a global business with manufacturing sites spanning three continents.

We deliver exceptional products and services that people ultimately rely on to enjoy a better quality of life.

Our range of raw materials includes antigens, antibodies, enzymes and serum and plasma products. We manufacture world renowned labels for lateral flow and ELISA, including our gold nanoparticles, horseradish peroxidase and alkaline phosphatase. Our glucose oxidase is used in over 5 billion blood glucose monitoring test strips every year.

We offer end to end outsourced development and manufacturing services across a number of lateral flow and related platforms. Over 25 years, we have successfully completed more than 250 projects. Using the latest technologies and platforms, customers have come to rely on BBI to deliver next generation assay performance.

BBI Solutions is part of the BBI Group.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRATIBLTMBJMBFA

(END) Dow Jones Newswires

December 07, 2015 02:00 ET (07:00 GMT)

1 Year Healthcare Inv Chart

1 Year Healthcare Inv Chart

1 Month Healthcare Inv Chart

1 Month Healthcare Inv Chart

Your Recent History

Delayed Upgrade Clock